NEW YORK (GenomeWeb) – SolveBio has been awarded a $1.5 million Phase II Small Business Innovation Research grant from the National Institutes of Health to continue development of a cloud-based genetic variation analysis and visualization system called Variant Explorer.
According to SolveBio, Variant Explorer enables researchers to identify sequenced variants that correlate with drug resistance or response, determine the molecular functional consequences of significant variants found in patients, and explore the relevant clinical and experimental evidence for understanding a given variant.
"This new NIH grant will allow us to continue to work with our biopharma partners to develop analytics tools, algorithms, and interfaces to harness new technologies, especially NGS and liquid biopsy, to achieve this vision and accelerate precision medicine-based therapeutic development," SolveBio CEO Mark Kaganovich said in a statement.
In mid-2016, SolveBio received a Phase I SBIR grant to begin developing Variant Explorer. The Phase II award started on Jan. 1 and runs through the end of 2019.